Presentation is loading. Please wait.

Presentation is loading. Please wait.

Proteome changes associated with CHCHD2 expression in NSCLC cells.

Published byBrice Daniel Modified over 5 years ago

Similar presentations

Presentation on theme: "Proteome changes associated with CHCHD2 expression in NSCLC cells."— Presentation transcript:

1 Proteome changes associated with CHCHD2 expression in NSCLC cells.
Proteome changes associated with CHCHD2 expression in NSCLC cells. A, Venn diagram depicting the number of nonredundant proteins identified in CHCHD2 knockdown, rescue/overexpression (RES/OE), and control (NSC) groups. Label-free quantitative proteome analysis was performed on six NSCLC cell lines (NSC, knockdown, and RES/OE derivatives of HCC827 and LPC43). B, enriched GO biologic process terms from proteins differentially expressed between CHCHD2 knockdown and control cells. Yuhong Wei et al. Mol Cancer Res 2015;13: ©2015 by American Association for Cancer Research

Download ppt "Proteome changes associated with CHCHD2 expression in NSCLC cells."

Similar presentations

Enhanced DNA damage in IDH1 mutant glioma cells.

Enhanced DNA damage in IDH1 mutant glioma cells.
IL-1β differentially regulates CXCL5 and CXCL8 protein secretion in NHTBE and NSCLC cells. IL-1β differentially regulates CXCL5 and CXCL8 protein secretion.

IL-1β differentially regulates CXCL5 and CXCL8 protein secretion in NHTBE and NSCLC cells. IL-1β differentially regulates CXCL5 and CXCL8 protein secretion.
A, structure drawing of LY

A, structure drawing of LY
Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.

Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.
A quantitative proteomics strategy to identify SUMO-conjugated proteins. A quantitative proteomics strategy to identify SUMO-conjugated proteins. HeLa.

A quantitative proteomics strategy to identify SUMO-conjugated proteins. A quantitative proteomics strategy to identify SUMO-conjugated proteins. HeLa.
Figure 3. Genes differentially expressed in batch cultures during adaptation to low temperature. Genes differentially expressed in batch cultures during.

Figure 3. Genes differentially expressed in batch cultures during adaptation to low temperature. Genes differentially expressed in batch cultures during.
IL32 prompts cell activation and cancer-related pathways.

IL32 prompts cell activation and cancer-related pathways.
Frequency distribution of the GRAVY of the theoretical proteins (open bars) and of 110 genes encoding proteins identified on a 2-D electrophoresis gel,

Frequency distribution of the GRAVY of the theoretical proteins (open bars) and of 110 genes encoding proteins identified on a 2-D electrophoresis gel,
Relative quantitation of phosphopeptides from conditioned media from subtype specific breast cancer cell lines. Relative quantitation of phosphopeptides.

Relative quantitation of phosphopeptides from conditioned media from subtype specific breast cancer cell lines. Relative quantitation of phosphopeptides.
Expression of apocrine markers at various stages of apocrine carcinoma progression. Expression of apocrine markers at various stages of apocrine carcinoma.

Expression of apocrine markers at various stages of apocrine carcinoma progression. Expression of apocrine markers at various stages of apocrine carcinoma.
Representative example of LAXIC performance for complex plant phosphoproteome. Representative example of LAXIC performance for complex plant phosphoproteome.A.

Representative example of LAXIC performance for complex plant phosphoproteome. Representative example of LAXIC performance for complex plant phosphoproteome.A.
NanoLC-MS/MS/based analysis of proteome differences between colonospheres and isogenic differentiated tumor cells. NanoLC-MS/MS/based analysis of proteome.

NanoLC-MS/MS/based analysis of proteome differences between colonospheres and isogenic differentiated tumor cells. NanoLC-MS/MS/based analysis of proteome.
Cluster analysis and pathway-based characterization of differentially expressed genes and proteins from integrated proteomics. Cluster analysis and pathway-based.

Cluster analysis and pathway-based characterization of differentially expressed genes and proteins from integrated proteomics. Cluster analysis and pathway-based.
BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere cells. BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere.

BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere cells. BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere.
Colonopshere-enriched proteins display functional interactions.

Colonopshere-enriched proteins display functional interactions.
Identification of SUMO3peptides from 2D-LC-MS/MS analyses of a tryptic digest of HEK293-SUMO3 cells using DDA and DIA methods. Identification of SUMO3peptides.

Identification of SUMO3peptides from 2D-LC-MS/MS analyses of a tryptic digest of HEK293-SUMO3 cells using DDA and DIA methods. Identification of SUMO3peptides.
Analysis of newly synthesized proteins by combined pulsed SILAC and click chemistry enrichment. Analysis of newly synthesized proteins by combined pulsed.

Analysis of newly synthesized proteins by combined pulsed SILAC and click chemistry enrichment. Analysis of newly synthesized proteins by combined pulsed.
Altered pathways in prostate cancer.

Altered pathways in prostate cancer.
Distribution of the phosphoproteins based on GO analysis, including biological process (Left) and cellular component (Right). Distribution of the phosphoproteins.

Distribution of the phosphoproteins based on GO analysis, including biological process (Left) and cellular component (Right). Distribution of the phosphoproteins.
Differential expression of apoA-I and Vimentin on 2D gels

Differential expression of apoA-I and Vimentin on 2D gels

Similar presentations

Ads by Google